IMRX
Immuneering Corporation
$7.66
0.15
(2%)
| Exchange: | |
| Market Cap: | 278.076M |
| Shares Outstanding: | 13.511M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Benjamin J. Zeskind | |||||
| Full Time Employees: | 54 | |||||
| Address: |
|
|||||
| Website: | https://immuneering.com |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
Could not create stock discussion for IMRX
